Skip to content

Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)

Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03492216
Acronym
DIPT
Enrollment
680
Registered
2018-04-10
Start date
2018-04-16
Completion date
2022-08-02
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS, Tuberculosis

Brief summary

There is an urgent global need to decrease the high mortality of tuberculosis (TB) in persons with HIV as TB is the leading cause of death among persons with HIV worldwide. The DIPT (Drinkers' Intervention to Prevent TB) study is a randomized, 2x2 factorial trial among HIV/TB co-infected adults in Uganda with heavy alcohol use (n=680 persons, 340 each U01). The goal of the study is to determine whether economic incentive interventions can promote both reduced alcohol use and isoniazid (INH) pill taking among HIV/TB co-infected adult heavy drinkers, during isoniazid preventive therapy (IPT: a six-month course of INH) at HIV clinics in southwestern Uganda. Participants will be randomized to one of four arms: Arm 1: no incentives (control); Arm 2: economic incentives for decreasing alcohol use only; Arm 3: economic incentives for IPT adherence only; Arm 4: economic incentives for decreasing alcohol use and for IPT adherence (rewarded independently).

Detailed description

TB is the leading cause of death among persons with HIV worldwide, and HIV-infected drinkers are at very high risk for TB disease and mortality. Globally, an estimated 25% of persons with HIV are heavy drinkers, and the risk of TB disease is 3-fold higher among heavy drinkers compared to non-drinkers. Six months of isoniazid (INH) preventive therapy (IPT) reduces TB morbidity and mortality by 30-50% above the benefit of antiretroviral therapy (ART). However, INH can be toxic to the liver, and as a result in many high TB/HIV prevalence settings, such as east Africa, heavy drinkers are not offered IPT. Thus interventions to reduce alcohol use are needed to decrease INH toxicity during IPT among HIV/TB infected drinkers. It is also well established that heavy drinkers have poorer ART adherence, and there is growing evidence of reduced IPT adherence in drinkers. However, interventions to reduce drinking have had limited impact on ART adherence, and further interventions to increase IPT adherence among HIV/TB infected drinkers are likely needed. The use of incentives to promote healthy behavior is a highly effective approach for reducing substance use and for improving adherence to HIV and TB regimens in resource-rich settings. Economic incentives to reduce alcohol use may create a window for safe and effective IPT use over six months by decreasing hepatotoxicity. Decreases in alcohol use may also improve IPT adherence, or additional incentives for IPT adherence may be needed. Such strategies to reduce alcohol use have not been studied in low-income countries and the effectiveness of incentives to optimize IPT in HIV/TB co-infected drinkers is unknown. OBJECTIVES Aim 1: Alcohol Reduction Intervention: Determine the effectiveness of economic incentives contingent on point-of-care (POC) urine ethyl glucuronide (EtG) \<300 ng/mL (Arms 2 & 4) versus no alcohol incentives (Arms 1 & 3) to reduce heavy drinking over 6 months, among HIV/TB co-infected adult drinkers receiving IPT. The investigators will randomize participants to low-cost escalating prize incentives for EtG negative urine tests at IPT refill visits (Arms 2+4), versus no incentives (Arms 1+3). Aim 2: INH Adherence Intervention: Determine the effectiveness of economic incentives contingent on POC (IsoScreen) INH urine positive tests (Arms 3 & 4) versus no INH incentives (Arms 1 & 2) on INH adherence among HIV/TB co-infected adult drinkers. The investigators will randomize participants to low-cost escalating prize incentives for INH positive urine tests at IPT refill visits (Arms 3+4), versus no incentives (Arms 1+2). Aim 3: Impact Assessment of Intervention: Assess the impact of economic incentives on HIV virologic suppression and explore their mechanisms of action, six months after trial completion. The investigators will follow all study participants for six months after trial completion. 1. Assess the impact of the 3 separate incentive interventions (Arms 2, 3, 4) vs. no incentives (Arm 1) on HIV virologic suppression. 2. Explore the mechanisms that may drive the economic incentives to increase virologic suppression. Potential mediators will be reductions in alcohol use and level of IPT adherence. This study will leverage new low-cost POC tests for alcohol use and INH pill-taking for the first study of incentive-based alcohol and adherence interventions in low-resource settings; these interventions may improve the safety and effectiveness of life-saving medications for heavy alcohol users in many settings.

Interventions

BEHAVIORALIncentives for negative EtG test

Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.

BEHAVIORALIncentives for positive IsoScreen test

Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.

Sponsors

Infectious Diseases Research Collaboration, Uganda
CollaboratorOTHER
Mbarara University of Science and Technology
CollaboratorOTHER
University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
SINGLE (Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV-infected adult (≥18 years) prescribed antiretroviral therapy (ART) for at least 6 months; * Current heavy alcohol use (AUDIT-C positive for prior 3 month drinking and positive EtG urine test); * Positive tuberculin skin test (TST) (≥5 mm induration); * AST and ALT \<2x the upper limit of normal (ULN); * Fluent in Runyankole or English; * No history of active TB, TB treatment, or TB preventive therapy; * Lives within 2-hour travel time or 60 km of the study site.

Exclusion criteria

* Prescribed nevirapine (NVP, an ART drug that is declining in usage due to high risk for hepatotoxicity); * Plans to move out of the catchment area within 6 months; * Prescribed anti-convulsion medications or history of recurring seizures; * ALT or AST elevations (\>2X ULN); * Suspected or confirmed active TB as determined by symptom screening and followed by chest X-ray and sputum testing; * History of prior active TB treatment or prior IPT. * Pregnant at time of screening

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With and Without Non-hazardous Drinking, as Determined by Self-report and the Biomarker Phosphatidylethanol, at 3- and 6-months.Both 3 months and 6 months (composite measure)Non-hazardous drinking is a composite outcome, measured at both 3 and 6 months. An individual must meet criteria for non-hazardous drinking (Alcohol Use Disorders Identification Test - Consumption \[AUDIT-C\], prior 3 months, negative) and phosphatidylethanol (PEth) \<35 ng/mL) at both time-points (3- and 6-months) in order to achieve the outcome.
Number of Participants With >90% Isoniazid (INH) Adherence During Prescribed Course of INH6 monthsIsoniazid (INH) adherence percentage is defined as the number of days with \>0 pill bottle openings divided by the number of prescribed doses, times 100. Pill bottle openings are captured by the Medication Event Monitoring System (MEMS) pill cap, with no more than 1 opening per day counted. The INH adherence outcome is INH adherence percentage, dichotomized as \>90% versus \<= 90%.

Secondary

MeasureTime frameDescription
Number of Participants With Hepatotoxicity Resulting in Isoniazid (INH) Discontinuation.up to 9 monthsIsoniazid (INH) treatment discontinuation due to a Grade 3+ hepatotoxicity at any time during the treatment period. Grade 3 hepatoxicity is defined by lab and/or clinical criteria as alanine transaminase (ALT) or aspartate transaminase (AST) elevation ≥5 (but \<10) times the upper limit of normal and/or symptoms consistent with hepatotoxicity; and Grade 4 as ALT or AST elevation ≥10 times the upper limit of normal or potentially life-threatening symptoms.
INH Concentration in Hair3 and 6 monthsSecondary Outcome. INH concentration in hair captures INH adherence over a period of weeks to months. Hair samples collected at the 3- and 6-month study visits will be analyzed for INH concentration.
Number of Participants With and Without HIV Viral Suppression at 12 Months12 monthsThe percentage of study participants with HIV viral load suppression (defined as \<200 copies/ml) at 12 months post-enrollment.
Number of Participants With Active Tuberculosis (TB).12 monthsSecondary Outcome. Number of participants diagnosed with active TB, within the 12 months of study follow-up.

Countries

Uganda

Participant flow

Recruitment details

Study recruitment occurred from April 2018 through July 2021. 5,508 persons were screened and 680 persons were enrolled and randomized.

Participants by arm

ArmCount
Control
All participants will receive brief alcohol and adherence counseling according to Uganda Ministry of Health guidelines.
169
Escalating Incentives (Ethyl Glucuronide [EtG] Tests)
Escalating incentives for ethyl glucuronide (EtG) negative urine test (Intervention: Incentives for negative EtG test). Incentives for negative EtG test: Economic incentives are given to the study participant contingent on point-of-care urine EtG \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.
169
Escalating Incentives (IsoScreen Tests)
Escalating incentives for IsoScreen positive urine tests (Intervention: Incentives for positive IsoScreen test). Incentives for positive IsoScreen test: Economic incentives contingent on point-of-care IsoScreen (Isnoiazid, INH) urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
170
Escalating Incentives (Ethyl Glucuronide [EtG] + IsoScreen)
Escalating incentives for ethyl glucuronide (EtG) negative tests and for IsoScreen positive urine tests with the incentives rewarded separately (Interventions: Incentives for negative EtG test and Incentives for positive IsoScreen test). Incentives for negative EtG test: Economic incentives are given to the study participant contingent on point-of-care (POC) urine EtG \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test. Incentives for positive IsoScreen test: Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
172
Total680

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall StudyDeath1040
Overall StudyIncarcerated0020
Overall StudyLost to Follow-up9278
Overall StudyMoved5335
Overall StudyToo ill0100
Overall StudyWithdrawal by Subject5311

Baseline characteristics

CharacteristicEscalating Incentives (Ethyl Glucuronide [EtG] Tests)Escalating Incentives (IsoScreen Tests)Escalating Incentives (Ethyl Glucuronide [EtG] + IsoScreen)ControlTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
5 Participants3 Participants3 Participants2 Participants13 Participants
Age, Categorical
Between 18 and 65 years
164 Participants167 Participants169 Participants167 Participants667 Participants
Age, Continuous38 years40 years39 years40 years39 years
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Uganda
169 participants170 participants172 participants169 participants680 participants
Sex: Female, Male
Female
53 Participants53 Participants53 Participants51 Participants210 Participants
Sex: Female, Male
Male
116 Participants117 Participants119 Participants118 Participants470 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
1 / 1690 / 1694 / 1700 / 172
other
Total, other adverse events
64 / 16950 / 16955 / 17039 / 172
serious
Total, serious adverse events
5 / 1695 / 1698 / 1704 / 172

Outcome results

Primary

Number of Participants With >90% Isoniazid (INH) Adherence During Prescribed Course of INH

Isoniazid (INH) adherence percentage is defined as the number of days with \>0 pill bottle openings divided by the number of prescribed doses, times 100. Pill bottle openings are captured by the Medication Event Monitoring System (MEMS) pill cap, with no more than 1 opening per day counted. The INH adherence outcome is INH adherence percentage, dichotomized as \>90% versus \<= 90%.

Time frame: 6 months

Population: As pre-specified in the Study Protocol, participants in the INH incentive arms (3 + 4) were compared to those in the no INH incentive arms (1 + 2).~INH incentive group (arms 3 + 4): 335/342 participants are included; 7 are excluded.~No INH incentive group (arms 1 + 2): 321/338 participants are included; 17 are excluded.

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Alcohol IncentivesNumber of Participants With >90% Isoniazid (INH) Adherence During Prescribed Course of INH>90% INH adherence244 Participants
Alcohol IncentivesNumber of Participants With >90% Isoniazid (INH) Adherence During Prescribed Course of INH<=90% INH adherence91 Participants
No Alcohol IncentivesNumber of Participants With >90% Isoniazid (INH) Adherence During Prescribed Course of INH>90% INH adherence234 Participants
No Alcohol IncentivesNumber of Participants With >90% Isoniazid (INH) Adherence During Prescribed Course of INH<=90% INH adherence87 Participants
p-value: 0.943595% CI: [-7, 6.5]Regression, Logistic
Primary

Number of Participants With and Without Non-hazardous Drinking, as Determined by Self-report and the Biomarker Phosphatidylethanol, at 3- and 6-months.

Non-hazardous drinking is a composite outcome, measured at both 3 and 6 months. An individual must meet criteria for non-hazardous drinking (Alcohol Use Disorders Identification Test - Consumption \[AUDIT-C\], prior 3 months, negative) and phosphatidylethanol (PEth) \<35 ng/mL) at both time-points (3- and 6-months) in order to achieve the outcome.

Time frame: Both 3 months and 6 months (composite measure)

Population: As pre-specified in the Study Protocol, participants in the EtG incentive arms (2 + 4) were compared to those in the no EtG incentive arms (1 + 3).~EtG incentives (arms 2 + 4): 323/341 participants included; 18/341 participants excluded.~No EtG incentives (arms 1 + 3): 313/339 participants included; 26/339 participants excluded.

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Alcohol IncentivesNumber of Participants With and Without Non-hazardous Drinking, as Determined by Self-report and the Biomarker Phosphatidylethanol, at 3- and 6-months.Non-hazardous alcohol use at 3 and 6 months = yes57 Participants
Alcohol IncentivesNumber of Participants With and Without Non-hazardous Drinking, as Determined by Self-report and the Biomarker Phosphatidylethanol, at 3- and 6-months.Non-hazardous alcohol use at 3 and 6 months = no266 Participants
No Alcohol IncentivesNumber of Participants With and Without Non-hazardous Drinking, as Determined by Self-report and the Biomarker Phosphatidylethanol, at 3- and 6-months.Non-hazardous alcohol use at 3 and 6 months = yes31 Participants
No Alcohol IncentivesNumber of Participants With and Without Non-hazardous Drinking, as Determined by Self-report and the Biomarker Phosphatidylethanol, at 3- and 6-months.Non-hazardous alcohol use at 3 and 6 months = no282 Participants
p-value: 0.002595% CI: [2.7, 12.5]Regression, Logistic
Secondary

INH Concentration in Hair

Secondary Outcome. INH concentration in hair captures INH adherence over a period of weeks to months. Hair samples collected at the 3- and 6-month study visits will be analyzed for INH concentration.

Time frame: 3 and 6 months

Population: Only participants in the INH adherence incentive arms had INH concentration in hair analyzed.

ArmMeasureGroupValue (MEDIAN)
Escalating Incentives (IsoScreen Tests)INH Concentration in Hairat 3 months49.4 pmol INH + AcINH / mg hair
Escalating Incentives (IsoScreen Tests)INH Concentration in Hairat 6 months49.3 pmol INH + AcINH / mg hair
Escalating Incentives (Ethyl Glucuronide [EtG] + IsoScreen)INH Concentration in Hairat 3 months49.1 pmol INH + AcINH / mg hair
Escalating Incentives (Ethyl Glucuronide [EtG] + IsoScreen)INH Concentration in Hairat 6 months57.1 pmol INH + AcINH / mg hair
Secondary

Number of Participants With Active Tuberculosis (TB).

Secondary Outcome. Number of participants diagnosed with active TB, within the 12 months of study follow-up.

Time frame: 12 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Alcohol IncentivesNumber of Participants With Active Tuberculosis (TB).0 Participants
No Alcohol IncentivesNumber of Participants With Active Tuberculosis (TB).1 Participants
Escalating Incentives (IsoScreen Tests)Number of Participants With Active Tuberculosis (TB).2 Participants
Escalating Incentives (Ethyl Glucuronide [EtG] + IsoScreen)Number of Participants With Active Tuberculosis (TB).1 Participants
Secondary

Number of Participants With and Without HIV Viral Suppression at 12 Months

The percentage of study participants with HIV viral load suppression (defined as \<200 copies/ml) at 12 months post-enrollment.

Time frame: 12 months

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Alcohol IncentivesNumber of Participants With and Without HIV Viral Suppression at 12 MonthsHIV viral suppression = yes144 Participants
Alcohol IncentivesNumber of Participants With and Without HIV Viral Suppression at 12 MonthsHIV viral suppression = no4 Participants
No Alcohol IncentivesNumber of Participants With and Without HIV Viral Suppression at 12 MonthsHIV viral suppression = no8 Participants
No Alcohol IncentivesNumber of Participants With and Without HIV Viral Suppression at 12 MonthsHIV viral suppression = yes147 Participants
Escalating Incentives (IsoScreen Tests)Number of Participants With and Without HIV Viral Suppression at 12 MonthsHIV viral suppression = yes146 Participants
Escalating Incentives (IsoScreen Tests)Number of Participants With and Without HIV Viral Suppression at 12 MonthsHIV viral suppression = no3 Participants
Escalating Incentives (Ethyl Glucuronide [EtG] + IsoScreen)Number of Participants With and Without HIV Viral Suppression at 12 MonthsHIV viral suppression = yes146 Participants
Escalating Incentives (Ethyl Glucuronide [EtG] + IsoScreen)Number of Participants With and Without HIV Viral Suppression at 12 MonthsHIV viral suppression = no2 Participants
p-value: 0.2695% CI: [-6.8, 1.9]Regression, Logistic
p-value: 0.795% CI: [-2.8, 4.1]Regression, Logistic
p-value: 0.4295% CI: [-1.9, 4.5]Regression, Logistic
Secondary

Number of Participants With Hepatotoxicity Resulting in Isoniazid (INH) Discontinuation.

Isoniazid (INH) treatment discontinuation due to a Grade 3+ hepatotoxicity at any time during the treatment period. Grade 3 hepatoxicity is defined by lab and/or clinical criteria as alanine transaminase (ALT) or aspartate transaminase (AST) elevation ≥5 (but \<10) times the upper limit of normal and/or symptoms consistent with hepatotoxicity; and Grade 4 as ALT or AST elevation ≥10 times the upper limit of normal or potentially life-threatening symptoms.

Time frame: up to 9 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Alcohol IncentivesNumber of Participants With Hepatotoxicity Resulting in Isoniazid (INH) Discontinuation.13 Participants
No Alcohol IncentivesNumber of Participants With Hepatotoxicity Resulting in Isoniazid (INH) Discontinuation.10 Participants
Escalating Incentives (IsoScreen Tests)Number of Participants With Hepatotoxicity Resulting in Isoniazid (INH) Discontinuation.15 Participants
Escalating Incentives (Ethyl Glucuronide [EtG] + IsoScreen)Number of Participants With Hepatotoxicity Resulting in Isoniazid (INH) Discontinuation.9 Participants

Source: ClinicalTrials.gov · Data processed: Jul 22, 2026